The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Dichlorphenamide (Brand name: Keveyis)
- Manufactured by
FDA-approved indication: Treatment of primary hyperkalemic periodic paralysis, primary hypokalemic period paralysis, and related variants
National Library of Medicine Drug Information Portal